Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment-Reference-Cited by-同舟云学术

Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment

Published:2016-01-22 Issue:10 Volume:10 Page:1186-1193
ISSN:1873-9946
Container-title:Journal of Crohn's and Colitis
language:en
Short-container-title:ECCOJC

Author:

Carpio D.,Jauregui-Amezaga A.,de Francisco R.,de Castro L.,Barreiro-de Acosta M.,Mendoza J. L.,Mañosa M.,Ollero V.,Castro B.,González-Conde B.,Hervías D.,Sierra Ausin M.,Sancho del Val L.,Botella-Mateu B.,Martínez-Cadilla J.,Calvo M.,Chaparro M.,Ginard D.,Guerra I.,Maroto N.,Calvet X.,Fernández-Salgado E.,Gordillo J.,Rojas Feria M.

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,General Medicine

Link

http://academic.oup.com/ecco-jcc/article-pdf/10/10/1186/8081154/jjw022.pdf

Reference83 articles.

1. Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn’s disease – the mechanisms of action of infliximab;Van Deventer;Alim Pharmacol Ther,1999

2. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease

3. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis

4. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety

5. Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. (Re-)introduction of TNF antagonists and JAK inhibitors in patients with previous tuberculosis: a systematic review;Clinical Microbiology and Infection;2024-08

2. Tuberculosis infection in patients with inflammatory bowel diseases. Clinacal cases;Terapevticheskii arkhiv;2023-12-22

3. The safety of vedolizumab in a patient with Crohn’s disease who developed anti-TNF-alpha agent associated latent tuberculosis infection reactivation: A case report;Medicine;2023-07-14

4. New‐onset extrapulmonary tuberculosis in negative latent tuberculosis infection screening patients with Crohn's disease under anti‐TNF therapy in a tuberculosis‐endemic region: A case series;Journal of Digestive Diseases;2023-05

5. Active tuberculosis in inflammatory bowel disease patients: a case–control study;Therapeutic Advances in Gastroenterology;2023-01